Skip to content

Dyne Therapeutics, Inc. DYN Offering Costs Included In Accounts Payable Or Accrued Expenses

Offering Costs Included In Accounts Payable Or Accrued Expenses at other companies

TRV
Trevi Therapeutics, Inc.TRVI
$58.25K
TRV
Trevi Therapeutics, Inc.TRVI
$58.25K
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$0-100%
Immunome logo
ImmunomeIMNM
$0-100%
Septerna, Inc. logo
Septerna, Inc.SEPN
$0-100%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$136K

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept dyn:OfferingCostsIncludedInAccountsPayableOrAccruedExpenses.

The official record: Dyne Therapeutics, Inc.’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s offering costs included in accounts payable or accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s offering costs included in accounts payable or accrued expenses?
Dyne Therapeutics, Inc. (DYN) reported offering costs included in accounts payable or accrued expenses of $106K in Q4 2025.
What does offering costs included in accounts payable or accrued expenses mean?
This metric captures the accrued costs related to equity offerings, such as underwriting fees or legal expenses, that have been recognized as liabilities but not yet settled with cash. It allows for a more accurate assessment of the total capital-raising costs incurred during a period. Monitoring these accruals is essential for understanding the net proceeds effectively realized from equity financing activities.